Skylar Jeremias

Researchers sought to determine the influence of geographic distance from a hospital on patients' length of stay or emergency department presentation for chronic obstructive pulmonary disease.

Activity trackers, like Fitbits, are not accurate enough for clinical use but may be helpful for coaching in conditions like COPD, a study says.

A new study has found that muscle loss can lead to increased rates of mortality and morbidity in patients with chronic obstructive pulmonary disease (COPD). However, one expert remains skeptical whether the study represents the full scope of patients at risk.

Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.

A shorter course of pulmonary rehabilitation, with phone support, improved symptoms and reduced hospital readmissions for patients with post-acute exacerbation in chronic obstructive pulmonary disease (AECOPD).

A study looking at the ways in which different countries handle appraisal and reimbursement processes for rare disease treatments (RDTs) revealed that implementing supplemental processes can aid in patient and physician decision making.

By delivering helpful information and fostering online communities, social media may provide rehabilitation and psychological benefits for patients with multiple sclerosis (MS) who have depression, according to the results of a recent Iranian study.

Hemophilia care principles have been on the rise in Europe over the course of the last decade, however, differing regions and policies on the continent reveal gaps in access to various treatments and specialty services.

Researchers called for new guidance to address the underreporting of patient engagement in rare disease clinical trials after finding a dismal amount of patient-reported outcome measures listed in orphan drug labeling claims.

Clinical trial result revealed that upadacitinib may be more effective in treating patients with rheumatoid arthritis than the gold standard of care, methotrexate.

Authors hope that identifying knowledge gaps surrounding rare blood cancers, such as essential thrombocythemia and polycythemia vera, will inspire the science community to invest in new comprehensive research on how to properly diagnose and treat patients.

A Taiwanese study revealed that attributes associated with polycystic ovary syndrome (PCOS) may increase the risks of those patients developing psoriasis as well.

A study analyzing patients with psoriasis revealed that personality traits may have a greater impact on the development of social anxiety than disease severity.

A review on the effects of Janus kinase (JAK) inhibitors for the treatment of myelofibrosis, including the first approved, ruxolitinib, and others currently in development.

The impact of psoriatic arthritis on quality of life can vary depending on geographic location and culture, according to a global patient survey.

A study conducted by Mayo Clinic researchers revealed that a combined treatment featuring daratumumab in conjunction with the standard-of-care for patients with amyloid light-chain (AL) amyloidosis was more effective in improving the condition than the standard treatment alone.

Studies with better data are still needed to fully understand the epidemiology of Duchenne muscular dystrophy (DMD), according to a recently published review.

Authors of an opinion piece concluded that not only are immunosuppressed patients with psoriasis not at an increased risk of developing serious complications related to coronavirus disease 2019 (COVID-19), their medications may help mitigate potential issues.

A data analysis of real-world data found that the rise of orphan drugs (ODs) in the Republic of Korea has not solved all patient accessibility issues as budget concerns can make it difficult to justify reimbursements.

A recent analysis describes the effects of the pandemic, including restrictions on outdoor activities and loss of income, on patients with psoriasis in China earlier this year.

The presentation at Virtual ISPOR 2020 found that 7% of a group of Medicare beneficiaries with type 2 diabetes was experiencing food insecurity, a rate the lead author found "alarming."

Ruxolitinib was found to be more cost-effective than the best available therapy (BAT) when the willingness-to-pay threshold for payers was at $150,000 and applied to patients with hydroxyurea resistant/intolerant polycythemia vera (PV) without splenomegaly, according to a new study.

Samsung Bioepis announced positiive trial results for its ranibizumab biosimilar (SB11).

A patient’s sex, disease duration, and residence were the most common sociodemographic factors shown to affect illness acceptance, life satisfaction, sense of stigmatization, and quality of life among those who have psoriasis, according to the results of a recent study.

In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions, speakers said this week during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.

Platelet function may aid in determining disease severity for patients with psoriasis who are at an increased risk of developing cardiovascular disease (CVD) and increased inflammation, a review notes.

Expanding access to biosimilar pegfilgrastim (Ziextenzo) for patients at intermediate risk of febrile neutropenia and converting patients at high risk who are on the reference product (Neulasta) could save millions in healthcare costs, according to new study results.

Guidelines created by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) address care management and treatment options for patients with psoriasis in relation to the increased risk of developing inflammatory, cardiovascular, and metabolic conditions.

Although the results have to be confirmed in a larger clinical trial, the researchers hope that the biomarker could be a noninvasive marker of a rare pediatric liver disease.

The FDA Friday approved pemigatinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.